Evaluation of endostatin levels in COVID-19 patients admitted to the emergency department

Basit Öğe Kaydı
dc.contributor.authorAkdur, Gökhan
dc.contributor.authorBardakcı, Okan
dc.contributor.authorDaş, Murat
dc.contributor.authorAkman, Canan
dc.contributor.authorŞehito?lu, Hilal Müserref
dc.contributor.authorAkdur, Okhan
dc.date.accessioned2026-02-03T11:53:31Z
dc.date.available2026-02-03T11:53:31Z
dc.date.issued2025
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractIntroduction: The COVID-19 is defined as a respiratory and endothelial disease caused by Severe Acute Respiratory Syndrome Coronavirus 2. Endostatin is a molecule bound to collagen in the basal membrane of endothelial cells. Objective: The aim of this study was to measure the serum endostatin levels of patients diagnosed with COVID-19 in the emergency department. Methods: This study was conducted in the emergency department with two groups: COVID-19 PCR-positive patients and healthy adults. Complete blood count, serum biochemistry values, and radiological imaging results were evaluated. Serum endostatin levels were measured from venous blood samples collected during the emergency department visits. Data were analyzed using the SPSS 19.0 software. Results: A total of 148 COVID-19 patients and 35 healthy controls were included in the study. The serum endostatin levels of the COVID-19 patient group were significantly lower compared to the healthy control group (p<0.05). The Chest CT Severity Score, 4C-Mortality Score, Quick SOFA, and Quick COVID-19 Severity Index were significantly higher in the patients with a fatal outcome compared to those who survived (p<0.001). Although serum endostatin levels were slightly higher in the fatal outcome group, no statistically significant difference was observed (p>0.05). Conclusion: There is no increase in serum endostatin levels in patients with COVID-19 presenting to the emergency department. While a slight increase in endostatin levels was observed in patients with a fatal outcome, it is believed that endostatin will not be effective in predicting prognosis. © 2025, Societe Tunisienne des Sciences Medicales. All rights reserved.
dc.description.sponsorshipÇanakkale Onsekiz Mart Üniversitesi, COMU, (2021-3633)
dc.description.sponsorshipÇanakkale Onsekiz Mart Üniversitesi, COMU
dc.identifier.doi10.62438/tunismed.v103i9.6017
dc.identifier.endpage1277
dc.identifier.issn0041-4131
dc.identifier.issue9
dc.identifier.scopus2-s2.0-105023094766
dc.identifier.scopusqualityQ3
dc.identifier.startpage1272
dc.identifier.urihttps://doi.org/10.62438/tunismed.v103i9.6017
dc.identifier.urihttps://hdl.handle.net/20.500.12428/34202
dc.identifier.volume103
dc.indekslendigikaynakScopus
dc.language.isoen
dc.publisherSociete Tunisienne des Sciences Medicales
dc.relation.ispartofTunisie Medicale
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_Scopus_20260130
dc.subjectCOVID-19
dc.subjectEmergency Department
dc.subjectEndostatin
dc.subjectPrognosis
dc.subjectPulmonary Injury
dc.titleEvaluation of endostatin levels in COVID-19 patients admitted to the emergency department
dc.title.alternativeÉvaluation des niveaux d'endostatine chez les patients atteints de COVID-19 admis aux urgences
dc.typeArticle

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu